Clinical trial Recruiting at 9 sites Observational Ages 18 to 90 Women only

Long-term safety of nipple sparing mastectomy for women with genetic breast cancer risk

Official title: Long-term Oncologic Safety of Nipple Sparing Mastectomy in Women With High Penetrance Germline Pathogenic Variants in Breast Cancer Susceptibility Genes

Run by Sir Mortimer B. Davis - Jewish General Hospital · NCT06888388 · Data updated 2026-11-12

This study is testing the long-term safety of nipple-sparing mastectomy for women with a genetic risk of breast cancer to see if it’s a good option for those who want to keep their nipple area.

More Breast Surgery trials

Quick facts

Study typeObservational
Ages18 Years to 90 Years
SexWomen only
Enrollment4700 (estimated)
SponsorSir Mortimer B. Davis - Jewish General Hospital
Academic / other
Locations16 sites (New Haven, Connecticut and 15 other locations)
StatusRecruiting
StartedFebruary 1, 2025
Main results expectedFebruary 1, 2027
Study endsFebruary 1, 2028
Registry record updatedAugust 18, 2026
Trial IDNCT06888388 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are women aged 18 and older with confirmed GPV in BRCA1, BRCA2, PALB2, TP53, CDH1, or PTEN.

Probably not a fit

Patients with a history of breast or ovarian cancer prior to genetic testing or those with a variant of uncertain significance may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the long-term safety of nipple sparing mastectomy (NSM) in women with germline pathogenic variants (GPV) in high-penetrance breast cancer susceptibility genes. It aims to provide data on the oncologic safety of NSM compared to traditional mastectomy techniques, as many patients desire to preserve their nipple areola complex for improved psychosocial and sexual well-being. The study will gather information from patients considering risk-reducing mastectomy to assess outcomes and safety over time.

Why it matters

Potential benefit: If successful, this study could provide critical evidence supporting the safety of nipple sparing mastectomy, enhancing patient quality of life and body image.

How similar studies have gone: Previous studies have shown low rates of subsequent breast cancer in BRCA1/2 carriers following nipple sparing mastectomy, suggesting potential success for this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Assigned female sex at birth
* Age 18 years or older
* Confirmed GPV in BRCA1, BRCA2, PALB2, TP53, CDH1 or PTEN identified on pre-symptomatic genetic testing

Exclusion Criteria:

* History of breast cancer prior to genetic testing
* History of ovarian cancer prior to genetic testing
* History of bilateral mastectomy performed prior to genetic testing
* Presence of a variant of uncertain significance (VUS) in the absence of another GPV in BRCA1, BRCA2, PALB2, TP53, CDH1 or PTEN.

Where it's running

  • Yale University
    New Haven, Connecticut, United States
    Recruiting
  • University of Pennsylvania
    Philadelphia, Pennsylvania, United States
    Recruiting
  • University of Calgary
    Calgary, Alberta, Canada
    Recruiting
  • Hamilton Health Sciences
    Hamilton, Ontario, Canada
    Recruiting
  • Jewish General Hospital
    Montreal, Quebec, Canada
    Recruiting
  • CHU de Quebec Université laval
    Québec, Quebec, Canada
    Recruiting
Show 10 more locations
  • Cancer Institute Hospital of JFCR, Tokyo
    Tokyo, Japan
    Recruiting
  • Asan Medical Centre
    Seoul, South Korea
    Recruiting
  • Belfast Health & Social Care Trust
    Belfast, United Kingdom
    Recruiting
  • Brigham and Women's Hospital - Dana-Farber Brigham Cancer Center
    Boston, Massachusetts, United States
    Not yet recruiting
  • Memorial Sloan Kettering Cancer Center (MSKCC)
    New York, New York, United States
    Not yet recruiting
  • University of Rochester, Wilmot Cancer Institute
    Rochester, New York, United States
    Not yet recruiting
  • University of Melbourne, Peter MacCallum Cancer Center
    Melbourne, Australia
    Not yet recruiting
  • Ziekenhuis Aan de Stroom
    Antwerp, Belgium
    Active not recruiting
  • Women's College Hospital, University of Toronto
    Toronto, Ontario, Canada
    Not yet recruiting
  • Champalimaud Foundation, University of Lisbon
    Lisbon, Portugal
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.